Salus Provide Best Price Flibanserin powder

[freemexy]

Salus Provide Best Price Flibanserin powder

Flibanserin is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three.Raw Cardarine powder

Quick Details
CAS No.:
147359-76-0
Other Names:
2H-Benzimidazol-2-one
MF:
C20H21F3N4O
EINECS No.:
167933-07-5
Place of Origin:
Shaanxi, China, Shaanxi, China (Mainland)
Type:
Antipyretic Analgesics and NSAIDs, Auxiliaries and Other Medicinal Chemicals
Grade Standard:
Food Grade, Medicine Grade, Tech Grade
Usage:
Animal Pharmaceuticals, Animal Pharmaceuticals
Brand Name:
salus
Model Number:
sa-flibanserin powder price
Purity:
99%min, ≥99.0%, ≥99.0%
Product Name:
flibanserin powder price
Appearance:
White Powder
CAS:
147359-76-0
Grade:
Food Grade, Medicine Grade, Tech Grade
Brand:
salus
Shelf life:
2 Years
Color:
White Color
1.Flibanserin is used for hypoactive sexual desire disorder among women.
Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”.In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
2.The effectiveness of flibanserin was evaluated in three phase 3 clinical trials.
Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced an increase in the number of SSEs and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire, and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase.